Tela Bio, INC

TELA Bio announced third quarter 2026 financial results, highlighting a 21% sequential reduction in operating loss and a strategic cost-saving initiative aimed at extending cash runway.

TELA Bio, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, leading to the decision not to proceed with a previously considered reverse stock split.

TELA Bio, Inc. announced it has regained compliance with the Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Global Market.

TELA Bio announced U.S. FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement.

TELA Bio, Inc. has entered into a Limited Consent to its Credit Agreement, temporarily suspending the minimum Revenue covenant test for two fiscal quarters.

TELA Bio, Inc. received a notice from Nasdaq indicating its common stock is subject to delisting due to a sustained low bid price, prompting the company to request a hearing and propose a reverse stock split.

TELA Bio, Inc. announced its third-quarter 2025 results, reporting a 9% revenue increase to $20.7 million and a 17% reduction in net loss, alongside a new $70 million credit facility and a $13 million direct offering.

TELA Bio, Inc. announced significant revenue growth and a narrower net loss for the second quarter of 2025, driven by new customer additions and product launches, despite continued overall losses.

TELA Bio's first quarter 2025 revenue increased by 12% year-over-year, but the company's net loss also significantly increased due to various factors including the absence of a gain from the sale of a product line that occurred in the prior year.

TELA Bio's Q3 2024 results show a 26% increase in revenue year-over-year, alongside a reduced net loss and the implementation of cost-cutting measures.

TELA Bio's Q2 2024 results show a revenue increase driven by higher unit sales, alongside a strategic sale of a product line, impacting overall profitability.

TELA Bio's first quarter 2024 results show a significant revenue increase of 39% year-over-year, driven by higher unit sales of both OviTex and OviTex PRS products.

TELA Bio, a medical technology company, reported a 16% increase in revenue to $80.3 million for 2025, alongside a net loss of $38.8 million, as it expands its soft-tissue reconstruction product portfolio.

TELA Bio, Inc. announces a 19% increase in revenue for 2024, driven by growth in OviTex and OviTex PRS product sales, while reducing its net loss by 19%.

TELA Bio, Inc. reports a significant 41% revenue increase in its 2023 annual filing, driven by strong sales of its OviTex and OviTex PRS products.

Joseph H Capper, a Director of TELA Bio, Inc., received 19,801 shares of common stock on October 15, 2026.

William J. Plovanic, a Director of TELA Bio, Inc., received 16,089 shares of common stock on October 15, 2026.

Joseph H Capper, a Director of TELA Bio, Inc., purchased 75,000 shares of common stock on September 14, 2026.

Heather C Getz, Chief Executive Officer and a Director of TELA Bio, Inc., purchased 12,500 shares of common stock on August 17, 2026 for $0.66 per share.

Heather C Getz, Chief Executive Officer and a Director of TELA Bio, Inc., purchased 15,000 shares of common stock on August 14, 2026 for $0.70 per share.

William J. Plovanic, a Director of TELA Bio, Inc., received 20,930 shares of common stock on July 15, 2026.

TELA Bio, Inc. is holding a special meeting on October 8, 2026, to vote on a reverse stock split aimed at increasing its share price to comply with Nasdaq listing rules.

TELA Bio, Inc. announces its 2026 Annual Meeting of Stockholders, featuring a significant board refreshment and a proposal to increase equity incentive plan shares.

TELA Bio, Inc. will hold its annual stockholder meeting virtually on May 28, 2025, and proxy materials are now available online.

TELA Bio, Inc. is holding its 2025 Annual Meeting of Stockholders virtually on May 28, 2025, to vote on several key proposals, including the election of directors, ratification of the independent auditor, executive compensation, and amendments to the equity incentive plan and corporate charter.

TELA Bio, Inc. will hold its annual stockholder meeting virtually on June 4, 2024, and proxy materials are now available online.

TELA Bio, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 4, 2024, featuring proposals for director elections and auditor ratification.

EW Healthcare Partners filed a Schedule 13D reporting the appointment of an affiliated operating partner to the TELA Bio, Inc. Board of Directors.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 6,545,596 shares, representing 14.5% of TELA Bio, Inc.'s common stock as of September 30, 2026.

North Run Capital, LP and affiliated entities report a passive beneficial ownership of 7.8% of TELA Bio, Inc.'s common stock as of September 30, 2026.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.8% of Tela Bio, Inc.'s Class A Common Stock as of June 30, 2026.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.8% of TELA BIO, Inc.'s Class A Common Stock as of June 30, 2026.

Laurence W. Lytton has disclosed beneficial ownership of 2,442,341 shares, representing 5.5% of the outstanding common stock of TELA Bio, Inc., as of March 31, 2026.

EW Healthcare Partners and its affiliates have increased their beneficial ownership in TELA Bio, Inc. to an aggregate of 17.32% of common stock following a recent direct offering.